PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Dermatomiosite e Polimiosite Dermatomiosite e Polimiosite 12 R eferências bibliográficas 1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-7. 2. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al., International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52(9): 2607-15. 3. Brenol CV, Xavier RM. Semiologia do Sistema Locomotor. In: Barros E, Albuquerque GC, Pinheiro CTS, Czepielewski MA, editores. Exame clínico - consulta rápida. 2ª ed. Porto Alegre: ArtMed; 2004. p. 510. 4. Firestein GS, Kelley WN. Kelley’s textbook of rheumatology. Philadelphia: Saunders; 2009. 5. Miller ML, Rudnicki SA. Initial treatment of dermatomyositis and polymyositis in adults [Internet]. Waltham (MA): UpToDate; 2009 [cited 2010 May 18]. Available from: http://www.uptodate.com/ patients/content /topic.do?topicKey=~ v_wcVHBb7M0w&selectedTitle=1~150. 6. Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83(1):35-42. 7. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28(10):2230-7. 8. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8): 403-7. 9. Reichlin M, Arnett FC Jr. Multiplicity of antibodies in myositis sera. Arthritis Rheum. 1984;27(10): 1150-6. 10. Gunawardena H, Betteridge ZE, McHugh NJ, Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48(6):607-12. 11. Buchbinder R, Forbes A, hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy- proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087-95. 12. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, Opava CH, Lundenberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 2007;57(5):768-77. 13. Alexanderson H, Stenström CH, Jenner G, Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol. 2000;29(5):295-301. 14. Escalante A, Miller L, Beardmore TD. Resistive exercise in the rehabilitation of polymyositisdermatomyositis. J Rheumatol. 1993;20(8):1340-4. 15. Choy EH, Hoogendijk JE, Lecky B, Winer JB, Gordon P. WITHDRAWN: Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2009;(4):CD003643. 16. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother. 2009;10(7):1183-90. 17. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94(4):379-87. 18. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980;92(3):365-9. 19. Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 1981;24 (1):45-8. 20. Vencovský J, Jarosová K, Machácek S, Studýnková J, Kafková J, Bartunková J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol, 2000;29(2):95-102. 21. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41(3):392-9. 22. DalakasMC, Illa I,DambrosiaJM, SoueidanSA, SteinDP,OteroC, et al.Acontrolled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27): 1993-2000. 23. Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46(2):467-74. 24. Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high- 167